Investigators at UF Health are seeking participants who have been diagnosed with both type 2 diabetes and kidney disease for a new clinical research study involving an investigational compound that may help maintain well-being for individuals at high risk of developing serious medical complications.
Individuals with type 2 diabetes have a greater risk of developing chronic health problems associated with the disease — including diabetic nephropathy, which occurs in approximately 40 percent of all patients with diabetes, according to the Journal of the American Medical Association. This can significantly add to the already substantial costs of medical care for these individuals.
The SONAR study will evaluate the impact of an investigational drug on renal outcomes, such as the onset of kidney failure or end-stage renal disease (ESRD), as defined by need for chronic dialysis, transplant or death due to renal failure progression.
Diabetes is the most common cause of kidney failure and accounts for nearly 44 percent of new cases in the US. Some experts predict that diabetes may soon account for half of all cases. The study will shed new light on the kidney and the drug’s possible cardiovascular protective effects and “demonstrates a critical need to develop safe, effective therapies for a patient population with the highest unmet medical need among those with diabetes,” says Karen Hall, MD, Director of the Family Medicine Residency Program at the University of Florida (UF) and Principal Research Investigator for the study.
The study will be double-blinded, so neither participants nor the study’s clinical staff will know who is receiving the investigational drug and who is receiving placebo. Duration of the trial will continue until enough participants have enrolled and have completed all scheduled appointments.
For more information about this study, e-mail danielletaylor@ufl.edu or call (352)-265-9552.